Vetr cut shares of Gilead Sciences, Inc. (NASDAQ:GILD) from a strong-buy rating to a buy rating in a research report report published on Thursday. Vetr currently has $74.34 price target on the biopharmaceutical company’s stock.
Other research analysts have also recently issued research reports about the company. BMO Capital Markets reaffirmed a hold rating and set a $76.00 target price (up previously from $75.00) on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Maxim Group reaffirmed a hold rating on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Barclays PLC reaffirmed an overweight rating and set a $85.00 target price on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Stifel Nicolaus reaffirmed a buy rating and set a $87.00 target price on shares of Gilead Sciences in a research note on Monday, April 24th. Finally, Robert W. Baird reaffirmed an outperform rating and set a $87.00 target price on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of Buy and an average price target of $80.61.
Gilead Sciences (NASDAQ:GILD) traded down 0.585% during midday trading on Thursday, reaching $65.564. The company’s stock had a trading volume of 1,706,213 shares. Gilead Sciences has a 1-year low of $65.38 and a 1-year high of $88.85. The company has a market capitalization of $85.69 billion, a price-to-earnings ratio of 6.929 and a beta of 1.11. The company’s 50-day moving average price is $67.09 and its 200-day moving average price is $70.95.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. On average, analysts predict that Gilead Sciences will post $8.21 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by sleekmoney and is owned by of sleekmoney. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://sleekmoney.com/gilead-sciences-inc-gild-downgraded-by-vetr-inc-2/1825616.html.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.15%. The ex-dividend date is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio is 18.91%.
In other news, Director John Francis Cogan sold 9,943 shares of the stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. Following the transaction, the director now owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $67.18, for a total value of $4,926,510.94. Following the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $214,973,917.42. The disclosure for this sale can be found here. In the last three months, insiders have sold 88,276 shares of company stock worth $5,932,578. 1.40% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Gilead Sciences by 2,789.0% in the first quarter. BlackRock Inc. now owns 102,969,463 shares of the biopharmaceutical company’s stock worth $6,993,686,000 after buying an additional 99,405,266 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Gilead Sciences by 7.3% in the first quarter. Vanguard Group Inc. now owns 90,693,263 shares of the biopharmaceutical company’s stock worth $6,159,886,000 after buying an additional 6,197,361 shares in the last quarter. State Street Corp raised its position in shares of Gilead Sciences by 4.5% in the fourth quarter. State Street Corp now owns 60,448,831 shares of the biopharmaceutical company’s stock worth $4,328,739,000 after buying an additional 2,587,072 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after buying an additional 2,727,063 shares in the last quarter. Finally, Parnassus Investments CA raised its position in shares of Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after buying an additional 4,556,901 shares in the last quarter. 74.19% of the stock is currently owned by institutional investors and hedge funds.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
To view Vetr’s full report, visit Vetr’s official website.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/gilead-sciences-inc-gild-downgraded-by-vetr-inc-2/1825616.html
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.